Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.


TSXV:NRX - Post by User

Post by ElliotGHon Feb 05, 2024 12:16pm
104 Views
Post# 35863241

$NRX gains traction in Europe with Orphan drug designation

$NRX gains traction in Europe with Orphan drug designation
NurExone gains traction in Europe with Orphan drug designation awarded by regulator (TSXV: NRX) (FSE: J90) (NRX.V)
 
https://10xalerts.com/nurexone-gains-traction-in-europe-with-orphan-drug-designation-awarded-by-regulator-tsxv-nrx-fse-j90-nrx-v/
<< Previous
Bullboard Posts
Next >>